Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down – Time to Sell?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price gapped down before the market opened on Friday . The stock had previously closed at $33.94, but opened at $29.50. Capricor Therapeutics shares last traded at $29.6340, with a volume of 491,712 shares traded.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. Piper Sandler reissued an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a report on Tuesday, March 10th. Finally, B. Riley Financial boosted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $46.09.

Capricor Therapeutics Stock Performance

The business has a fifty day simple moving average of $31.45 and a 200-day simple moving average of $23.34. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -12.98 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). On average, equities analysts anticipate that Capricor Therapeutics, Inc. will post 0.01 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, Director Karimah Es Sabar sold 61,265 shares of the company’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total value of $1,848,365.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the transaction, the chief financial officer owned 8,223 shares in the company, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 172,529 shares of company stock valued at $5,302,440. Insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at about $28,000. Parkside Financial Bank & Trust acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at about $36,000. Russell Investments Group Ltd. increased its stake in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 2,786 shares during the period. ACT Capital Management LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $43,000. Finally, KBC Group NV acquired a new stake in shares of Capricor Therapeutics in the first quarter valued at about $44,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.